Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Xencor (XNCR) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (74)	12/22/2014 9:52:50 PM
From: fitzdad55	Respond to of 136

For Affimed's lead bispecific, AFM13, its anti-CD30 drug currently in Ph2 (for HL), there are several papers, ranging from the preclinical work to Ph1. Unfortunately, the company doesn't include on its website some of the more prominent publications, so you have to ferret them out on the web. Here are three, at least one of which is related to an ASH presentation, another from AACR, and a third from ASCO: cancerres.aacrjournals.org meetinglibrary.asco.org bloodjournal.org